Ayala Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$1.1M
-0.1
-7.46
$10K
20
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. The company is headquartered in Monmouth Junction, New Jersey and currently employs 20 full-time employees. The company went IPO on 2005-07-28. The firm's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine.
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. The company is headquartered in Monmouth Junction, New Jersey and currently employs 20 full-time employees. The company went IPO on 2005-07-28. The firm's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.